8-K: Phreesia Appoints Jon Kessler to Board, Two Directors Retire
Board of Directors Update
Phreesia, Inc. announced the appointment of Jon Kessler to its Board of Directors, effective April 6, 2026, while Edward L. Cahill and Michael Weintraub will retire at the 2026 Annual Meeting.
Summary
- Edward L. Cahill and Michael Weintraub will retire from the Board of Directors at the end of their current terms and will not stand for re-election at the 2026 Annual Meeting of stockholders.
- Their retirements are not a result of any disagreement with the Board or management of the Company.
- Jon Kessler has been appointed to the Board as a Class I director, effective April 6, 2026.
- Mr. Kessler will receive a pro-rated annual grant for restricted stock units valued at $40,041 and an initial new hire grant for restricted stock units valued at $185,000.
- The Board's authorized number of directors was temporarily increased from eight to nine, effective April 6, 2026, and then decreased from nine to seven, effective immediately prior to the 2026 Annual Meeting.
- Following these changes, the Board will consist of seven directors, with six being independent.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a positive and strategic board refreshment. The addition of a highly experienced director like Jon Kessler, coupled with the orderly retirement of long-serving members, strengthens the company's governance and strategic capabilities, particularly given its strong growth metrics.
Positives
- The appointment of Jon Kessler, an experienced public company CEO and director with a strong track record in healthcare financial services and technology, is expected to bring valuable expertise to the Board.
- The company has demonstrated significant growth since its 2019 IPO, with revenue increasing from approximately $100 million to over $460 million for the twelve months ended October 31, 2025.
- Phreesia enabled approximately 170 million patient visits in 2024, representing nearly 1 in 7 visits across the U.S., indicating strong market penetration.
- The Board maintains a commitment to continually adding independent directors with highly relevant backgrounds, expertise, and skill sets.
Future Outlook
The company anticipates continued growth and impact by strengthening its platform, introducing new offerings, enhancing the patient experience, and driving value for shareholders, leveraging Jon Kessler's expertise in technology-driven growth and healthcare financial services.
Management Comments
- "Jons appointment reflects Phreesias commitment to maintaining a high-caliber Board by continually adding independent directors with highly relevant backgrounds, expertise and skill sets." Chaim Indig, CEO and Co-Founder of Phreesia.
- "His experience at two companies at the intersection of the consumer, financial and healthcare industries aligns closely with our mission to make care easier every day through innovative technology solutions." Chaim Indig.
- "Our discussions with Jon over the past months have made clear that his knowledge and background make him a valuable addition to our Board as we strengthen our platform, introduce new offerings, enhance the patient experience and drive value for shareholders." Chaim Indig.
- "I have long admired Phreesia for its leadership in modernizing the patient intake experience." Jon Kessler.
- "As I have had a chance to get to know members of the Board over the last few months, it has become clear to me that the Company is well positioned for continued growth and impact as it continues to address critical challenges across the healthcare ecosystem." Jon Kessler.
- "I am honored to join the Board and look forward to supporting Phreesias mission." Jon Kessler.
- "On behalf of the Board, I would like to express my gratitude to Ed and Michael for their many contributions as directors." Chaim Indig.
- "Their guidance was instrumental during our successful IPO in 2019 and continues to shape Phreesias growth strategy." Chaim Indig.
Industry Context
StockSavvy.ai notes that the appointment of Jon Kessler, a veteran from HealthEquity and WageWorks, underscores a broader industry trend in healthcare technology where companies seek leadership with deep expertise in financial services and technological innovation to navigate the evolving digital health landscape. His background in scaling companies at the intersection of consumer, financial, and healthcare industries is particularly relevant as patient engagement and financial aspects of care become increasingly integrated.
Comparison to Industry Standards
- Jon Kessler's experience as CEO of HealthEquity (NASDAQ:HQY), which scaled to an enterprise value of approximately $10 billion, and founder/CEO of WageWorks, which grew to $150 million in revenue in seven years, demonstrates a track record comparable to successful leaders in the healthcare financial services and technology sectors.
- Phreesia's growth from approximately $100 million revenue at its 2019 IPO to over $460 million for the twelve months ended October 31, 2025, indicates a strong growth trajectory, potentially outperforming some peers in the patient activation and digital health space.
- Enabling 170 million patient visits in 2024, representing nearly 1 in 7 visits across the U.S., positions Phreesia as a significant player in the patient intake and engagement market, suggesting a high level of market penetration relative to many specialized healthcare technology providers.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director, Member of Compensation Committee | Edward L. Cahill | NA | 2026 Annual Meeting | Retirement; will not stand for re-election. |
| Chair of the Board, Chair of Compensation Committee, Member of Nominating and Corporate Governance Committee | Michael Weintraub | NA | 2026 Annual Meeting | Retirement; will not stand for re-election. |
| Class I Director | NA | Jon Kessler | April 6, 2026 | Appointment to bring valuable expertise in healthcare financial services and technology. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Size Adjustment | The authorized number of directors was increased from eight to nine by increasing the size of Class I by one position, effective April 6, 2026. Subsequently, the authorized number of directors will decrease from nine to seven by decreasing the size of Class I by two positions, effective immediately prior to the 2026 Annual Meeting. | April 6, 2026 (increase); Immediately prior to 2026 Annual Meeting (decrease) | This adjustment facilitates the appointment of a new director while managing the overall board size following retirements, ensuring a streamlined and experienced board composition of seven directors, six of whom are independent. |
| Director Compensation Policy | Jon Kessler's compensation includes a pro-rated annual grant for restricted stock units valued at $40,041 and an initial new hire grant for restricted stock units valued at $185,000, consistent with the Third Amended and Restated Non-Employee Director Compensation Policy. | February 23, 2026 (grant date) | Ensures competitive compensation for new independent directors, aligning their interests with long-term shareholder value through equity grants. |
| Indemnification Agreement | Mr. Kessler will enter into the Company's standard form of indemnification agreement. | April 6, 2026 | Provides standard protection for the new director against liabilities incurred during their service, consistent with existing corporate governance practices. |
Stakeholder Impact
- Shareholders: The appointment of a highly experienced director like Jon Kessler, known for driving shareholder value, could be seen as a positive for strategic direction and long-term value creation. The orderly transition of board members also signals stable governance.
- Employees: No direct impact mentioned, but a strengthened board could lead to more robust strategic initiatives, potentially benefiting the company's overall health and employee opportunities.
- Customers: The focus on strengthening the platform, introducing new offerings, and enhancing the patient experience, as mentioned by the CEO, suggests potential improvements in products and services for healthcare providers and patients.
- Suppliers: No direct impact mentioned.
- Creditors: No direct impact mentioned.
Next Steps
- Jon Kessler will officially join the Board on April 6, 2026.
- Edward L. Cahill and Michael Weintraub will retire from the Board at the 2026 Annual Meeting of stockholders.
- A new Board Chair will be appointed upon Michael Weintraub's retirement.
- The Board will reduce its size to seven directors immediately prior to the 2026 Annual Meeting.
Key Dates
| Date | Description |
|---|---|
| 2019 | Phreesia's Initial Public Offering (IPO) year. |
| June 21, 2019 | Date of filing of the Company's Registration Statement on Form S-1, which includes the standard form of indemnification agreement. |
| 2024 | Year Phreesia enabled approximately 170 million patient visits. |
| October 31, 2025 | End of the twelve-month period for which Phreesia's revenue exceeded $460 million. |
| February 23, 2026 | Date of earliest event reported; Edward L. Cahill and Michael Weintraub submitted retirement notices, Jon Kessler was appointed to the Board, and Board size changes were approved. |
| April 6, 2026 | Effective date of Jon Kessler's appointment to the Board and the increase in authorized directors from eight to nine. |
| 2026 Annual Meeting | Expected date of retirement for Edward L. Cahill and Michael Weintraub, and the effective date for the decrease in authorized directors from nine to seven. |
Recommendation
holdThe filing details a strategic board refreshment with the addition of a highly experienced director and the orderly retirement of long-serving members. While the appointment of Jon Kessler is a positive development, signaling a focus on technology-driven growth and shareholder value, the filing does not contain new financial performance data beyond historical growth metrics. Therefore, a 'hold' recommendation is appropriate as investors should await further financial updates to assess the full impact of these governance changes on future performance.
Keywords
Phreesia, PHR, Board of Directors, Jon Kessler, Edward L. Cahill, Michael Weintraub, Corporate Governance, Director Appointment, Director Retirement, Healthcare Technology, Patient Activation, SEC Filing, 8-K
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.